Talking Urology

Damien Bolton & Andrew Weickhardt discuss ‘The COVID conundrum: loss and lessons learned.

Prof Thomas Powles joins Talking Urology to discuss the new measures of success with IO agents.

A/Prof Shariat is currently professor and chairman of the department of urology, Medical University of Vienna General Hospital, Austria. He is also adjunct professor of urology and medical oncology at Weill Cornell Medical Center, New York, and adjunct professor or urology at the University of Texas Southwestern Medical Center, Dallas, USA.

Prof Van Poppel is the Chairman of the Department of Urology at the University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Belgium. He is a Board Member of the European Association of Urology (EAU), the European Society of Surgical Oncology and the European Organization for Research and Treatment of Cancer, where he is also Study Coordinator and Treasurer of the Genito-Urinary Group. He is Chairman of the Educational Office of the EAU and Director of the European School of Urology.

Join the star-studded cast of Talking Urology with Neal Shore, Ben Tran and Joseph Ischia as they unearth the mysteries of non-metastatic CRPC

Dr. Klotz is the founding editor of the Canadian Urology Association Journal and is now the Editor Emeritus. He is chairman of the Canadian Urology Research Consortium and is a widely published uro-oncologist with over 300 publications and 4 books. His main research interest has been prostate cancer and was awarded the Queen's Jubilee Medal for meritorious public service.

Dr. Lin is Professor and Chief of Urologic Oncology in the Department of Urology and holds the Bridges Endowed Professorship for Prostate Cancer Research at the University of Washington School of Medicine. Dr. Lin's major basic/translational research interests are in prostate chemoprevention and molecular/genomic biomarkers for aggressive prostate cancer, and his major clinical research efforts are in prostate cancer active surveillance and novel strategies in high-risk prostate cancer.

Dr. Nitti is a Professor of Urology and OB/GYN, Vice-Chairman of Urology, Director of the Female Pelvic Medicine and Reconstructive Surgery at New York University Langone Medical Center. A graduate of the University of Medicine and Dentistry of New Jersey, Dr. Nitti completed his urology residency at SUNY Downstate in Brooklyn, NY and his fellowship in Female Urology, Neurourology, and Reconstructive Urology at UCLA. He is a Fellow of the American College of Surgeons and the American Board of Urology.

Dr. Quinn is currently the Medical Director of the Norris Cancer Hospital, the Head of Genitourinary Medical Oncology and Associate Professor of Medicine in the Division of Oncology, Keck School of Medicine, University of Southern California. He is a medical oncologist and an international expert in the field of clinical trials and molecular correlative studies in genitourinary cancer and early therapeutics.

Maurizio Brausi discusses his landmark paper on BCG in Intermediate & High-risk Ta, T1 Papillary Ca of the Bladder.

Dr Renu Eapen is a Consultant Urologist in the Genitourinary Oncology service at the Austin Hospital Olivia Newton-John Cancer Centre and the Peter MacCallum Cancer Centre. Dr Eapen undertook research in Female Pelvic Medicine and Reconstructive Surgery at University of Texas Southwestern Dallas. She went on to complete a subspecialty Fellowship at the University of Toronto, Canada and subsequently obtained her robotics and uro-oncology Fellowship at University of California, San Francisco. She is currently undertaking her PhD at the University of Melbourne. Axel Merseburger is Professor of Urology and Chairman of the Department of Urology at University Hospital Schleswig Holstein, Campus Lübeck, in Lübeck, Germany. He was appointed Associate Professor, in 2009, and Professor, in 2012, at Hannover Medical School. He is Principal Investigator for multiple phase 2 and phase 3 clinical trials. Prof. Merseburger is as an advisor for the European Association of Urology (EAU) Guidelines Group for Renal Cancer and has previously served as Chairman of the EAU Guidelines Group for Lasers and Technologies. Prof. Merseburger acts as a reviewer and editorial board member for several urology and oncology indexed journals, is Associate Editor of the World Journal of Urology, and is Editor-in-Chief of European Oncology & Haematology.

Joseph Ischia is outnumbered by exercise physiologists. Listen in as he co-hosts with Dale Ischia, Ashley Bigaran and special guest Eva Zopf. Dale Ischia is an Accredited Exercise Physiologist from Melbourne with over 20 years clinical experience. She founded ‘Moving Beyond Cancer’, an exercise physiology program dedicated to improving the lives of people with a cancer diagnosis through appropriately prescribed exercise. Ashley is an AEP and PhD candidate with a developing reputation as a junior researcher. She has over eight years’ experience as an AEP and has been employed in leading public and private health settings, high performance teams and university institutions. Ashley is the Co-Chair of the ESSA Victoria State Chapter and consults clinically at the Baker Institute’. Special guest, Dr Eva Zopf, is an exercise physiologist and completed her PhD in Exercise Oncology at the German Sport University in Cologne in Germany, she did a postdoctoral research fellowship at Edith Cowan University in Perth and is now a key member of the Exercise Oncology team at the Australian Catholic University.

Dr Estella graduated from the University of Queensland (Medicine) in 1994 with the prize in medicine therapeutics. His endocrine training commenced in Brisbane at the Princess Alexandra Hospital and the Greenslopes hospital. He has undertaken further studies and a PhD in the area of Type 1 diabetes. Dr Estella has authored many articles and medical papers and is dedicated in keeping up to date with the latest medical developments.

Professor Suzanne Chambers is the dean of the faculty of health at University of technology Sydney and previously, the director of the Menzies Institute at Griffith University. She is a health psychologist and registered nurse who has worked as a practitioner and researcher in psychological support for people with cancer for over 25 years. Professor Chambers was made an Officer of the Order of Australia in the 2018 Queen’s Birthday Honours for distinguished service to medical research, particularly in the area of psycho-oncology, and to community health through patient care strategies to assist men with prostate cancer. She has published extensively on the psychological effects of cancer with over 7000 citations of her work from leading journals in the field. Professor Chambers is currently chair of the Quality of Life and Supportive Care Committee for the Australian and New Zealand Urogenital and Prostate Cancer Trials Group and is also affiliated with Cancer Council Queensland and the Prostate Cancer Foundation of Australia. She holds adjunct professorships at Edith Cowan University, the University of Queensland and University of Southern Queensland.

Hosts Joseph Ischia and Victoria Cullen, along with special guest Richard Wassersug, discuss the impact of ADT on the sex life of patients with prostate cancer. Victoria Cullen is a Sexuality Educator and PhD candidate at RMIT University. She obtained her Bachelor’s degree and Masters in Cognitive Psychology from University College London. In 2015, Victoria co-founded the world's first sex toy design course in an academic setting at RMIT University and in 2017, she partnered with Urology Surgeon, Professor Declan Murphy, to deliver complimentary consultations to prostatectomy patients. She offers free online resources for sexual recovery post prostate cancer treatment through her website www.atouchysubject.com. Richard Wassersug is a research scientist and also a prostate cancer patient, based in Vancouver, Canada, where he holds the position of Honorary Professor in the Faculty of Medicine at the University of British Columbia. He has authored or coauthored over 300 academic papers in fields as diverse as human sexuality and amphibian biology. However, a major focus of his research for the last decade has been on the psychology of androgen deprivation. An over-arching goal of Dr.Wassersug’s work is to develop ways to help men and their partners recognize and overcome the side effect burden from androgen deprivation therapy, which is the primary treatment for systemic prostate cancer. This research led to the 2014 book “Androgen Deprivation Therapy: An essential guide for prostate cancer patients and their loved ones” for which he is the lead author. A 2ndedition was published in 2018, and the two editions together have sold ~70,000 copies. Dr. Wassersug is a Co-lead for Canada's Androgen Deprivation Therapy Educational Program.

So You’re Gonna . . . do a TURBT with Prof Lukas Lusuardi, Joseph Ischia & Nicholas Campbell.

In this ANZUP conference highlight, Henry Woo chats to Kelly Parsons Professor of Urology, UC San Diego. He is a clinician, a clinical triallist, and an author of wonderful and sometimes saucy medical fiction. Henry and Kelly explore the 5 key biases of urologists and surgeons, and why urologists need to get involved in clinical trial teams.

In this ANZUP conference highlight, Andrew Weickhardt chats with Betsy Plimack, Chief of the Division of Genitourinary Medical Oncology, Fox Chase Cancer Centre in the US. She talks about the future potential role of genetic mutations in urothelial cancer: can they predict response to treatments or even decide which treatments you should use? They also discuss the use of the new immuno-oncology agents in metastatic kidney cancer: what are the second line options, and how do we measure success of treatments- keep a close ear out for the emerging concept of treatment free survival as the yard stick for the immune-oncology agents.

In this ANZUP conference highlight, Andrew Weickhardt chats with Australia’s very own Ian Davis about ANZUP’s successful world leading phase 3 study, ENZAMET. Ian outlines ENZAMET for men with newly diagnosed metastatic hormone naïve prostate cancer and how it differs from the other trials involving second line anti-androgens in this space. Ian also discusses how you might decide between the myriad of treatment options that have now shown effect in the upfront hormone naïve metastatic setting.

In this ANZUP conference highlight, Kath Schubach chats to Catherine Paterson from the Department of Nursing and Midwifery, University of Canberra about some of the key messages from the nursing program at ANZUP how to improve the supportive care needs of patients with urological cancers.

In this ANZUP conference highlight, this year’s convenor David Pryor chats to Phuoc Tran, a radiation oncologist from John Hopkins, about his success with the Oriel trial of stereotactic radiation for patients with oligometastatic prostate cancer.

In this ANZUP conference highlight, Craig Gedye chats to Carole Harris, Patti Bastik & Antoinette Fontela, the investigators for the KEYPAD trial. They chat about what it is like to be involved in a clinical trial for the doctor and the patients, the barriers faced to running a successful clinical trial, the KEYPAD study investigating the addition of immuno-oncology agents plus denosumab, and the techniques they have used to improve the success of their trials.

Haryana Dhillon & Jasmine Yee talk about the beneficial role of exercise in patients with a cancer diagnosis with a particular focus on those with advanced cancers.

Prof Ian Davis chats with Prof David Quinn about the latest research for metastatic kidney cancer and the changes we’ve seen in first line treatments.

Dr Alison Birtle & Prof Ian Davis discuss the development and execution of the phase 3 POUT trial which has set the new standard of the benefit of adjuvant chemotherapy in men with locally advanced upper tract urothelial cancer after nephro-ureterectomy.

Prof Francesco Montorsi talks with Joseph Ischia & Nathan Lawrentshuk about the long and short of penile rehabilitation.

Talking Urology Series 2 Episode 1 – Join Joseph and Nathan as they talk with John Yaxley and discuss if robotic surgery achieves better outcomes than open surgery when it comes to radical prostatectomy.

Talking Urology conducted a series of live recordings at USANZ 2019 conference in Brisbane. Joseph Ischia discusses a range of topics with the following distinguished luminaries in the field of urology: Prof Axel Heidenreich, Dr Peter Burke, Dr Ian Vela, Dr Guido Barbagli, Prof Peter Gilling, Dr Jo Semins, Prof Scott Eggener, Dr Tim Donahue, Prof Alex Mottrie, A/Prof Peter Chin, Prof David Nicol, Prof James N’Dow & Prof Andrea Tubaro This Talking Urology conference summary is supported by Ipsen.

A/Professor Joseph Ischia and co-host Dr Rachel Esler talk with Prof Claus Roehrborn about the key literature and take home points for starting BPH patients on alpha-blocker therapy.

A/Prof Andrew Weickhardt discusses the CARMENA trial with A/Prof Laurence Albiges and Dr Monty Pal. Can we take away any positives from this negative trial?

A/Prof Laurence Albiges and Dr Monty Pal discuss the changing landscape and biomarkers in metastatic renal cell carcinoma with A/Prof Andrew Weickhardt.

Assistant Prof Angie Smith discusses the four types of BCG failure and subsequent management in patients with non-muscle invasive bladder cancer.

Dr Tombal explores the future of academic urology. How can we get surgeons back into research?

Prof Chris Sweeney discusses intermittent versus continuous ADT in metastatic hormone sensitive prostate cancer. Can you balance survival and quality of life?

Dr George Hruby dares to ask if you can radiate the prostate more than once.

Dr Haryana Dhillon: Are we doing enough to address anxiety and depression in patients with prostate cancer and what can we do about it?

Dr Joseph Ischia chats with ANZUP 2018 Convenor Henry Woo. Enjoy the highlights of the conference through the eyes of the convenor.

As ANZUP celebrates its 10th Anniversary, Prof Ian Davis reflects on how ANZUP brings people together to improve patient outcomes.

Dr Carmel Pezaro talks with Dr Ben Tran about ‘Bringing Data Back’. He’s sexy. He’s funny. You’ll love him.

Dr Niazi discusses prostate oligometastatic targeted therapy in castration resistant prostate cancer.

Dr Joseph Ischia chats with David Pryor, the convenor of the 2019 ANZUP conference in Brisbane July 21-23.

Lisa Horvath discusses her research on how a man's plasma lipid signature can predict prognosis in castration resistant prostate cancer

Peter Black discusses the potential new molecular classification of bladder cancers.

Lisa Butler discusses her research on identifying drug response biomarkers in prostate cancer

Homi Zargar discusses some of the controversies in kidney cancer management.

Craig Gedye discusses new biomarkers for kidney cancer.

Alex Kutikov discusses his new metric for determining the utility of MRI-US fusion prostate biopsy.

Prue Cormie discusses the multitude of benefits of exercise in men with prostate cancer.

Camille Short discusses her innovative website to support men underoging treatment for metastatic prostate cancer

Silke Gillessen discusses the interesting findings from the Advanced Prostate Cancer Consensus Conference in St Gallen.

Michael Hofman discusses the new ANZUP/PCFA trial investigating therapeutic Lutetium (Lu-177) PSMA for men with advanced mCRPC.